Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Vinepidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 5/20 | 0.83 |
| ▸ | TUBB known ✓ | P07437 | 5/20 | 0.83 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 5/20 | 0.83 |
| ▸ | TUBA1B known ✓ | P68363 | 5/20 | 0.83 |
| ▸ | TUBA4A known ✓ | P68366 | 5/20 | 0.83 |
| ▸ | TUBB4B known ✓ | P68371 | 5/20 | 0.83 |
| ▸ | TUBB3 known ✓ | Q13509 | 5/20 | 0.83 |
| ▸ | TUBB2A known ✓ | Q13885 | 5/20 | 0.83 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 5/20 | 0.83 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 5/20 | 0.83 |
| ▸ | TUBA1A known ✓ | Q71U36 | 5/20 | 0.83 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 5/20 | 0.83 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 5/20 | 0.83 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 5/20 | 0.83 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 5/20 | 0.83 |
| ▸ | MAPT | P10636 | 8/20 | 0.85 |
| ▸ | LMNA | P02545 | 6/20 | 0.85 |
| ▸ | MEN1 | O00255 | 6/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vinepidine SCHEMBL29376135 | 1.00 | MAPT (0.85) | MAPTLMNAMEN1KMT2AHIF1A | |
| Vinepidine SCHEMBL29385187 | 0.98 | LMNA (0.85) | MAPTLMNAMEN1KMT2AHIF1A | |
| Vinepidine SCHEMBL285304 | 0.98 | LMNA (0.85) | MAPTLMNAMEN1KMT2AHIF1A | |
| Roseamine SCHEMBL10059227 | 0.93 | MAPT (0.85) | MAPTLMNAMEN1KMT2AHIF1A | |
| Roseamine SCHEMBL30368397 | 0.93 | MAPT (0.85) | MAPTLMNAMEN1KMT2AHIF1A | |
| Vincristine SCHEMBL18398051 | 0.92 | MAPT (1.00) | MAPTLMNAMEN1KMT2AHIF1A | |
| Vincristine SCHEMBL3998 | 0.92 | MAPT (1.00) | MAPTLMNAMEN1KMT2AHIF1A | |
| Vincristine SCHEMBL3710 | 0.92 | MAPT (1.00) | MAPTLMNAMEN1KMT2AHIF1A | |
| Vincristine SCHEMBL2946485 | 0.92 | MAPT (1.00) | MAPTLMNAMEN1KMT2AHIF1A | |
| Vincristine SCHEMBL4640472 | 0.92 | MAPT (1.00) | MAPTLMNAMEN1KMT2AHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8847 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| US-12109219-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | claimed |
| WO-2024162488-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CUCURBITACIN D FOR PREVENTING OR TREATING NEUROPATHIC PAIN | 주식회사 재인알앤피 | 2024-08-08 | — | — | WO | claimed |
| EP-4401780-A1 | AMORPHOUS PHOTOSENSITIZING PARTICLES, METHODS FOR THE PREPARATION THEREOF, AND METHODS FOR THE USE THEREOF | University of Maryland, College Park (US) | 2024-07-24 | — | — | EP | claimed |
| WO-2024026505-A2 | DISRUPTION OF TELOCYTE ACTIVITY | PATEL AMIT (US) | 2024-02-01 | — | — | WO | claimed |
| WO-2023044436-A1 | AMORPHOUS PHOTOSENSITIZING PARTICLES, METHODS FOR THE PREPARATION THEREOF, AND METHODS FOR THE USE THEREOF | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2023-03-23 | — | — | WO | claimed |
| US-20220401541-A1 | INTRATUMORAL ADMINISTRATION OF IMMUNE CELLULAR THERAPEUTICS | FIBROBIOLOGICS, INC. | 2022-12-22 | — | — | US | claimed |
| EP-3441089-B1 | TREATMENT METHODS USING ADENOVIRUS | VASCULAR BIOGENICS LTD (IL) | 2022-12-14 | — | — | EP | claimed |
| WO-2008062466-A2 | CINNAMIC ACID, VANILLIC ACID AND BENZOFURAN DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATION AND CANCER | RELIANCE LIFE SCIENCES PVT. LTD. (IN) | 2008-05-29 | — | — | WO | claimed |
| WO-2008039254-A2 | RNA NANOPARTICLES AND NANOTUBES | GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-04-03 | — | — | WO | claimed |
| WO-2007059116-A2 | GELDANAMYCIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ABRAXIS BIOSCIENCE, INC. (US) | 2007-05-24 | — | — | WO | claimed |
| US-20060079472-A1 | Methods for treating angiogenesis | ANGIOSYN, INC. | 2006-04-13 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20040092583-A1 | Treatment for inhibiting neoplastic lesions | SHANAHAN-PRENDERGAST ELIZABETH (IE) | 2004-05-13 | — | — | US | claimed |
| EP-1351678-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | Shanahan-Prendergast, Elizabeth (IE) | 2003-10-15 | — | — | EP | claimed |
| WO-2002053138-A2 | TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS | SHANAHAN-PRENDERGAST ELISABETH (IE) | 2002-07-11 | — | — | WO | claimed |